Cary G. Vance, Chief Executive Officer
Cary G. Vance was appointed as President and Chief Executive Officer at OptiScan Biomedical on May 21, 2018. Mr. Vance has extensive leadership experience and a record of consistent achievement in transforming businesses and driving sustained growth for over 30 years. He previously served as President and Chief Executive Officer at Myoscience Incorporated, where he led the company in a turnaround effort towards unprecedented growth and profitability, strategically transforming the business and their markets with disruptive technology. He also served as President and Chief Executive Officer at Hansen Medical for over two years, where he led a turnaround effort that resulted in the successful sale of the company. Prior to Hansen, Mr. Vance served as President of the Anesthesia & Respiratory global business at Teleflex Incorporated and as their Executive Vice President North America. Before joining Teleflex, he was an executive at Covidien, and served as Vice President & General Manager of Interventional Oncology – Americas, and was the Vice President & General Manager for their Energy-based Devices unit for three years. Mr. Vance served in a series of roles with progressive responsibility at GE Healthcare from 1997 to 2007, principally in diagnostic imaging sales and marketing management, and executive leadership. Mr. Vance is Lean/Six Sigma Black Belt certified, and holds a B.A. in Economics and an M.B.A from Marquette University.
Patrick Nugent, Chief Financial Officer
Patrick Nugent is the CFO at OptiScan Biomedical. Mr. Nugent has over 16 years of extensive experience in raising capital, strategic and financial planning, audits and investor relations. Prior to joining OptiScan Biomedical, Mr. Nugent held the position of Chief Financial Officer at Pelikan Technologies Inc. Before that Mr. Nugent held the position of Chief Financial Officer and Executive Vice President of Finance for Telesensory Corporation for worldwide operations. Mr. Nugent has a bachelor’s degree in Accounting and Financial Management and is a Chartered Management Accountant from the Chartered Institute of Management Accountants of London, England.
Jim Causey, VP Research & Development
Jim Causey has been the VP, Research & Development of OptiScan since 2012. From 2005 to 2007, Mr. Causey was CEO of M2 Medical Technologies, a medical device start-up developing a next generation insulin pump. Directly prior to joining OptiScan, Mr. Causey had established his own consulting firm.
Mr. Causey was VP of Research & Development at MiniMed Inc. from 1997-2001, responsible for the development of MiniMed’s insulin pump products. While at MiniMed, he led the effort to introduce the most successful insulin pump in MiniMed’s history, either before or after the subsequent acquisition by Medtronic, Inc. Mr. Causey began his career at Pacesetter Systems in 1981, where he participated in and led the development of implantable pacemakers over a period of 15 years. Pacesetter was later acquired by St. Jude Medical. After that acquisition, Mr. Causey held the position of Vice President of Defibrillator Development, leading a team that introduced an industry-leading ICD.
Mr. Causey is a named inventor in over 90 allowed US patents. He has a pre-med Biology degree from CSUN, Northridge, California.
OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000/6000 system.